425: BioNTech Moves to Acquire CureVac in $1.25 Billion mRNA Technology Expansion

BioNTech SE has announced its intent to acquire CureVac N.V. through an exchange offer valued at approximately $1.25 billion, aiming to bolster its mRNA capabilities and pipeline.

Summary

• BioNTech SE is acquiring CureVac N.V. through an exchange offer, where CureVac shareholders will receive BioNTech American Depositary Shares (ADSs).
• The transaction is valued at an implied aggregate equity value for CureVac of approximately $1.25 billion.
• Each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs, subject to a collar mechanism based on BioNTech's ADS volume-weighted average price (VWAP).
• If BioNTech's 10-day VWAP exceeds $126.55, the exchange ratio will be 0.04318; if it falls below $84.37, the ratio will be 0.06476.
• Upon closing, CureVac will be delisted from NASDAQ, and its operating subsidiary will become a wholly-owned subsidiary of BioNTech.
• CureVac's research and manufacturing site in Tübingen, Germany, is expected to be integrated into BioNTech's operations until at least the end of 2027.
• The acquisition is intended to complement BioNTech's capabilities in mRNA design, delivery formulations, and manufacturing, aligning with its strategic focus on pan-tumor programs.
• Certain CureVac shareholders, including dievini Hopp BioTech holding GmbH & Co. KG and CureVac's management and supervisory boards, representing 36.76% of shares, have committed to supporting the transaction.
• The German Federal government, through Kreditanstalt für Wiederaufbau (holding 13.32% of CureVac shares), is also expected to support, bringing total expected commitments to 50.08% towards the 80% minimum condition.
• CureVac shareholders are expected to own between 4% and 6% of BioNTech post-transaction.

Sentiment

Score: 7

Explanation: The document outlines a strategic acquisition that strengthens BioNTech's core mRNA capabilities and pipeline, with significant shareholder support. While integration and regulatory risks exist, the overall tone is positive regarding strategic alignment and future value creation.

Positives

• The acquisition is expected to complement BioNTech's existing capabilities in mRNA design, delivery formulations, and manufacturing, potentially accelerating its pipeline development.
• Integration of CureVac's candidates into BioNTech's pipeline could broaden BioNTech's therapeutic areas, particularly in cancer immunotherapies, aligning with its re-focused strategy.
• The transaction structure, involving an exchange offer of BioNTech ADSs, is designed to support long-term value creation for both companies' shareholders and maintain BioNTech's financial flexibility.
• Significant shareholder support, totaling over 50% of CureVac shares, including key institutional and insider holders, indicates strong confidence in the deal's completion.
• The integration of CureVac's Tübingen manufacturing site provides BioNTech with additional production capacity and research infrastructure.

Negatives

• CureVac will be delisted from NASDAQ upon closing, which may impact liquidity for current CureVac shareholders who do not tender their shares.
• The integration of CureVac's operations and employees into BioNTech's ongoing group-wide transformation could present operational complexities and potential disruptions.
• The transaction is subject to customary closing conditions, including regulatory review by the US FTC and DOJ, which could introduce delays or require concessions.
• Shareholders who do not tender their shares in the exchange offer will ultimately receive the same consideration in a corporate reorganization, but without interest and subject to withholding taxes, potentially disincentivizing holding out.

Risks

• Uncertainties regarding the timing of the exchange offer and the subsequent corporate reorganization of CureVac.
• Uncertainties as to the number of CureVac shareholders who will tender their shares in the exchange offer.
• The risk that competing offers or acquisition proposals for CureVac may emerge.
• The possibility that various conditions to the consummation of the exchange offer and the transactions may not be satisfied or waived.
• The possibility of a termination of the Purchase Agreement between BioNTech and CureVac.
• Challenges in obtaining necessary regulatory approvals or obtaining them on acceptable terms or within expected timing.
• Potential disruption from the transactions, impacting BioNTech's and/or CureVac's business, including relationships with employees, business partners, or governmental entities.
• The risk that the exchange offer or other transactions may be more expensive to complete than anticipated.
• The risk that litigation in connection with the exchange offer or other transactions may result in significant costs of defense, indemnification, and liability.
• Diversion of management's attention from ongoing business operations and opportunities due to the exchange offer and transactions.
• General industry conditions and competition, including the impact of pharmaceutical industry regulation and healthcare legislation.
• Challenges and uncertainties inherent in new product development, including safety, quality, data integrity, or manufacturing issues.
• Ability to obtain or maintain proprietary intellectual property protection.
• Potential or actual data security and data privacy breaches.

Future Outlook

BioNTech plans to significantly invest in the broad clinical evaluation of two priority pan-tumor programs across multiple cancer indications, including mRNA cancer immunotherapies. The acquisition of CureVac is expected to support this strategy and align with BioNTech's portfolio management. Following the transaction, BioNTech intends to integrate CureVac's candidates into its pipeline and actively manage them based on strategic alignment, data, operational efficiency, and sustainable value creation. The integration of CureVac's Tübingen site is planned until at least the end of 2027.

Management Comments

• "We believe that the acquisition of CureVac will complement BioNTechs capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing."
• "This transaction structure (exchange offer) is quite common in the pharma/healthcare space. This approach is driven by takeover law in The Netherlands, which is the jurisdiction of organization of CureVac."
• "It is important to both BioNTech and CureVac to ensure that enrolled patients in ongoing clinical trials will continue to receive treatments."
• "BioNTechs vision remains unchanged, and the strategy has been further tailored to execute towards our mission of improving the health of patients in need."
• "BioNTech will develop an integration plan in alignment with its ongoing group-wide transformation, which BioNTech intends to finalize and implement after a successful closing."

Industry Context

This acquisition signifies a consolidation within the mRNA technology space, a sector that gained prominence during the COVID-19 pandemic. BioNTech, a leader in mRNA vaccines, is strategically expanding its capabilities and pipeline beyond infectious diseases into oncology, a key area for future mRNA applications. The move reflects a broader industry trend of leveraging advanced platform technologies for diverse therapeutic areas and consolidating expertise to accelerate drug development and manufacturing.

Comparison to Industry Standards

• The use of an exchange offer, particularly involving ADSs for a foreign-based company, is a common transaction structure in cross-border pharmaceutical and healthcare mergers, aligning with standard practices for international takeovers.
• The implied valuation of CureVac at approximately $1.25 billion reflects a significant investment in mRNA technology, comparable to other strategic acquisitions in the biotech sector focused on platform technologies and pipeline assets.
• The commitment from a substantial portion of CureVac's shareholders, including a significant institutional investor and insiders, is a positive indicator of deal certainty, often seen in successful strategic acquisitions within the industry.
• The emphasis on continuing ongoing clinical trials and patient treatments aligns with ethical and regulatory standards in the pharmaceutical industry during mergers, ensuring patient welfare and data integrity are maintained.

Corporate Governance

Legal Proceedings

• The document mentions the risk of litigation in connection with the exchange offer or other transactions contemplated by the Purchase Agreement, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Certain shareholders of CureVac representing 36.76% of CureVac's shares, including dievini Hopp BioTech holding GmbH & Co. KG and all members of CureVac's management and supervisory boards, have entered into tender and support agreements to tender their shares and vote in favor of the transaction. This constitutes a related party transaction due to their significant ownership and/or board positions.

Stakeholder Impact

• **Shareholders (CureVac):** Will receive BioNTech ADSs, becoming shareholders in BioNTech. Those not tendering will receive the same consideration in a subsequent reorganization. CureVac shares will be delisted from NASDAQ.
• **Shareholders (BioNTech):** Will see their company expand its mRNA capabilities and pipeline, potentially enhancing long-term value, but also experience dilution as new ADSs are issued.
• **Employees (CureVac):** Will be integrated into BioNTech, with an integration plan to be developed and employees assessed by the same evaluation criteria.
• **Patients:** Enrolled patients in ongoing clinical trials will continue to receive treatments, ensuring continuity of care and research.
• **Regulatory Bodies:** The transaction requires review and approval from US FTC and DOJ, and other customary regulatory bodies, ensuring compliance with antitrust and other laws.

Next Steps

• BioNTech intends to file a Registration Statement on Form F-4 with the SEC, including an offer to exchange/prospectus.
• BioNTech intends to file a Tender Offer Statement on Schedule TO with the SEC.
• CureVac intends to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• BioNTech will make considerable additional information available in press releases and filings in the coming weeks.
• An extraordinary general meeting of CureVac's shareholders will be convened to adopt resolutions relating to the transaction.
• BioNTech will develop and finalize an integration plan for CureVac's operations and employees after the successful closing of the transaction.

Key Dates

Keywords

BioNTech, CureVac, Acquisition, Merger, mRNA, Biotechnology, Pharmaceuticals, Exchange Offer, SEC Filing, NASDAQ Delisting, Clinical Trials, Tübingen, Corporate Governance, Regulatory Approval